|
Accueil > Actualité
Valneva: CHMP recommends extended indication for Ixchiq
(CercleFinance.com) - Valneva announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of the extension of the indication of IXCHIQ vaccine, Valneva's single-injection vaccine for the prevention of disease caused by the chikungunya virus, to people aged twelve and over.
IXCHIQ® had already received marketing authorization in Europe for people aged 18 and over in July 20241. The European Commission (EC) will now examine the CHMP's recommendation, and a decision on the application to extend the vaccine's indication in the European Union (EU), Norway, Liechtenstein and Iceland is expected within sixty days. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
03/03/2025 12:47
Verizonpartenariat en cybersécurité avec Accenture 03/03/2025 12:22 Stellantisdeux nouveaux administrateurs vont être proposés 03/03/2025 12:10 AccorBlackRock dépasse les 5% du capital 03/03/2025 12:07 Ericssonteste la 5G ferroviaire avec Qualcomm Technologies 03/03/2025 11:54 Nokiava fournir des solutions sans fil à Carrix 03/03/2025 11:52 bioMérieuxvisé par une plainte de l'allemand Qiagen Tous les articles sociétés |
